Why is Tenax Therapeutics stock collapsing today? By Investing.com
Investing.com -- Tenax Therapeutics stock plunged 84.2% in pre-open trading after the company disclosed that its Phase 3 LEVEL trial of TNX-103 -- oral levosimendan -- failed to meet its primary endpoint of a statistically significant improvement in 6-minute walk distance compared to placebo in patients with pulmonary hypertension due to heart failure with preserved ejection fraction, with a least-squares mean difference of just 3.5 meters and a p-value of 0.63. The trial also missed its key sec
Prepared by Olivia Bennett and reviewed by editorial team.
- Articles Published:
- 24
- Right Leaning:
- 0
- Left Leaning:
- 0
- Neutral:
- 24
- Distribution:
- Left 0%, Center 100%, Right 0%
Left: Highlighted regulatory oversight needs and patient clinical trial access risks. Center: Focused strictly on clinical data metrics and immediate market valuation losses. Right: Emphasized free-market capital reactions and corporate executive decision-making accountability.
Tenax Therapeutics press release issued August 10, 2026, detailing trial metrics. https://ir.tenaxthera.com/news-releases/news-release-details/tenax-therapeutics-announces-topline-results-phase-3-level
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
Why is Tenax Therapeutics stock collapsing today? By Investing.com
EventRegistry Reuters Investing Bloomberg Bloomberg The Wall Street Journal Marketwatch Cnbc Endpts Benzinga Yahoo Zacks Globenewswire Bioworld Statnews Tipranks Streetinsider Medicalxpress Clinicaltrialsarena Pharmexec Marketbeat Thestreet Barrons InvestorplaceFrom Right
No right-leaning sources found for this story.
Comments